Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMYMP) EBITDA (2016 - 2025)

Historic EBITDA for Bristol Myers Squibb (BMYMP) over the last 17 years, with Q4 2025 value amounting to $1.1 billion.

  • Bristol Myers Squibb's EBITDA rose 25596.03% to $1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $6.8 billion, marking a year-over-year increase of 17834.49%. This contributed to the annual value of $6.8 billion for FY2025, which is 17832.18% up from last year.
  • Latest data reveals that Bristol Myers Squibb reported EBITDA of $1.1 billion as of Q4 2025, which was up 25596.03% from $2.2 billion recorded in Q3 2025.
  • Over the past 5 years, Bristol Myers Squibb's EBITDA peaked at $2.5 billion during Q4 2021, and registered a low of -$11.8 billion during Q1 2024.
  • Its 5-year average for EBITDA is $988.4 million, with a median of $1.6 billion in 2021.
  • As far as peak fluctuations go, Bristol Myers Squibb's EBITDA surged by 76938.78% in 2021, and later tumbled by 64091.95% in 2024.
  • Bristol Myers Squibb's EBITDA (Quarter) stood at $2.5 billion in 2021, then crashed by 37.42% to $1.6 billion in 2022, then fell by 5.06% to $1.5 billion in 2023, then tumbled by 79.89% to $302.0 million in 2024, then skyrocketed by 255.96% to $1.1 billion in 2025.
  • Its EBITDA was $1.1 billion in Q4 2025, compared to $2.2 billion in Q3 2025 and $1.2 billion in Q2 2025.